Polyclonal Antibody to Chemokine (C-X-C Motif) Ligand 2 (CXCL2)
Code | Size | Price |
---|
PAB603Mu51-20ul | 20ul | £85.00 |
Quantity:
PAB603Mu51-100ul | 100ul | £156.00 |
Quantity:
PAB603Mu51-200ul | 200ul | £210.00 |
Quantity:
PAB603Mu51-1ml | 1ml | £479.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Guinea Pig
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
GROb; SCYB2; MIP2; GRO2; MIP2a; MGSAb; CINC2a; HSF; Macrophage inflammatory protein 2-alpha; Hematopoietic synergistic factor; Growth Regulated Oncogene Beta
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Immunogen:
EPB603Mu51-Eukaryotic Chemokine (C-X-C Motif) Ligand 2 (CXCL2)
Item Name:
Chemokine (C-X-C Motif) Ligand 2
Source:
Polyclonal antibody preparation
Subcategory:
Polyclonal antibody preparation
USAGE:
Western blotting: 0.5-2ug/mL
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL
Immunocytochemistry: 5-20ug/mL
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Growth Regulated Oncogene Beta (GROb) | EPB603Mu51 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||